# Melanotan 2 Research: Mechanism, Clinical Trials, and Preclinical Findings

> Melanotan 2 mechanism of action, Phase I and II human trial data, preclinical receptor pharmacology, and a comparative analysis of MT-2 vs MT-1. Cited editorial summaries from the published literature.

The Melanotan 2 research literature spans four decades, two small Phase I/II human trials, a substantial rodent preclinical record, and a growing pharmacovigilance body documenting adverse events in unregulated use. All dosing figures are research-protocol descriptions, not recommendations.

## Melanotan II Mechanism of Action

Melanotan II (MT-II) is a non-selective melanocortin receptor agonist. It binds MC1R, MC3R, MC4R, and MC5R with high affinity, coupling through Gs-protein to activate adenylyl cyclase and elevate intracellular cyclic AMP (cAMP).

At MC1R in cutaneous melanocytes, elevated cAMP activates PKA, which upregulates tyrosinase and drives the conversion of tyrosine into eumelanin pigment granules independently of ultraviolet radiation. [1] At MC4R, MT-II activates sympathetic nervous system tone, reduces food intake, and engages dopaminergic and oxytocinergic pathways that drive sexual arousal. Central MC4R agonism also upregulates GLUT4 mRNA in skeletal muscle. [12] At MC3R in the nucleus accumbens, MT-II dose-dependently reduced food intake without producing conditioned taste avoidance or altering metabolic rate. [6]

## MT-2 Peptide: Receptor Pharmacology

- **MC1R** — cutaneous melanocytes; drives eumelanin synthesis, anti-inflammatory signaling
- **MC3R** — hypothalamic arcuate nucleus and nucleus accumbens; energy homeostasis, feeding suppression [6]
- **MC4R** — hypothalamus, limbic system, spinal cord; sexual arousal, appetite suppression, thermogenesis [2][3][5][11]
- **MC5R** — exocrine glands; sebaceous secretion regulation

## Phase I and II Human Trial Data

The Dorr 1996 Phase I tanning study administered MT-II at 0.01–0.025 mg/kg SC to three healthy volunteers over ten days. [1] Two of three subjects showed measurable pigmentation increases. Spontaneous penile erections lasting 1–5 hours redirected the research program toward MC4R clinical study. [18]

The Wessells 1998 study (n=10): MT-II produced erections in 8 of 10 men with psychogenic erectile dysfunction, mean tip rigidity >80% for 38 minutes vs 3 minutes placebo (p=0.0045). [2] The 2000 expansion (n=20): 17 of 20 men achieved erections, tip rigidity >80% for 41 minutes, sexual desire increased after 68% of active vs 19% of placebo doses. [3] No Phase III trials for MT-II have been published.

## Melanotan 2 and Appetite

Cote 2017: 40-day chronic central melanocortin activation in rats reduced intra-abdominal fat by 35–55%, 3-fold BAT thermogenesis elevation; anorexic tolerance developed within 5 days but weight loss persisted. [5] Eliason 2022: intra-NAcc microinjection in mice dose-dependently reduced appetitive feeding, no conditioned taste avoidance. [6] Raposinho 2003: MT-II counteracted NPY-driven hyperphagia but did not affect LH pulsatility. [14]

## Melanotan 2 vs Melanotan 1

MT-I (afamelanotide) is a linear 13-amino-acid MC1R-selective analog; received EMA approval for erythropoietic protoporphyria. MT-II is a cyclic 7-amino-acid non-selective agonist; no regulatory approval anywhere. The clinical program most directly derived from MT-II is bremelanotide (PT-141), FDA-approved 2019 for HSDD.

## Peripheral Nerve Regeneration Research

Ter Laak 2003: subcutaneous MT-II at 20 mcg/kg q48h significantly enhanced sensory function recovery after sciatic nerve crush in rats; partial protection against cisplatin-induced toxic neuropathy. [13]

## Insulin Sensitivity

Heijboer 2005: ICV MT-II (225 ng total) in mice increased insulin-mediated glucose disposal in skeletal muscle, elevated GLUT4 mRNA. No change in body weight or food intake. [12]

## References

[1] Dorr RT et al. Life Sciences. 1996;58(20):1777-1784. https://pubmed.ncbi.nlm.nih.gov/8637402/
[2] Wessells H et al. Journal of Urology. 1998;160(2):389-393. https://pubmed.ncbi.nlm.nih.gov/9679884/
[3] Wessells H et al. International Journal of Impotence Research. 2000;12 Suppl 4:S74-S79. https://pubmed.ncbi.nlm.nih.gov/11035391/
[5] Cote I et al. Canadian Journal of Physiology and Pharmacology. 2017;95(2):206-214. https://pubmed.ncbi.nlm.nih.gov/28051332/
[6] Eliason NL et al. Neuropeptides. 2022;96:102289. https://pubmed.ncbi.nlm.nih.gov/36155088/
[11] Thurston L et al. Journal of Clinical Investigation. 2022;132(19):e152341. https://pubmed.ncbi.nlm.nih.gov/36189794/
[12] Heijboer AC et al. Diabetologia. 2005;48(8):1621-1626. https://pubmed.ncbi.nlm.nih.gov/15971058/
[13] Ter Laak MP et al. European Journal of Pharmacology. 2003;462(1-3):179-183. https://pubmed.ncbi.nlm.nih.gov/12591111/
[14] Raposinho PD et al. Journal of Neuroendocrinology. 2003;15(2):173-181. https://pubmed.ncbi.nlm.nih.gov/12535159/
[15] Paiva L et al. Journal of Neuroendocrinology. 2017;29(2):e12453. https://pubmed.ncbi.nlm.nih.gov/28009464/
[18] Hadley ME. Peptides. 2005;26(10):1687-1689. https://pubmed.ncbi.nlm.nih.gov/15996790/

---

An editorial reading of the peer-reviewed Melanotan 2 record — Phase I trials, preclinical mechanism studies, and pharmacovigilance case reports, indexed to source.